Cargando…

Efficacy analysis of combined detection of 5 Serological Tumor markers including MIF and PIVKA-II for early diagnosis of Primary Hepatic Cancer

OBJECTIVES: To investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal prothrombin (PIVKA-II) in the early diagnosis of primary liver cancer. METHODS: A total of 90 patients with suspected primary liver cancer...

Descripción completa

Detalles Bibliográficos
Autor principal:	Huan, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377914/ https://www.ncbi.nlm.nih.gov/pubmed/34475930 http://dx.doi.org/10.12669/pjms.37.5.4264

Ejemplares similares

Impact of PIVKA-II in diagnosis of hepatocellular carcinoma
por: Zakhary, Nadia I., et al.
Publicado: (2013)

Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients
por: Chen, Youran, et al.
Publicado: (2022)

Primary colon cancer with a high serum PIVKA-II level
por: Kato, Kazuya, et al.
Publicado: (2014)

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
por: Ren, Tianying, et al.
Publicado: (2023)

Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study
por: Tartaglione, Sara, et al.
Publicado: (2019)

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
por: Feng, Honglei, et al.
Publicado: (2021)

The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma
por: Lee, Qiuyan, et al.
Publicado: (2021)

Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
por: Chan, Henry L Y, et al.
Publicado: (2022)

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma
por: Tian, Shan, et al.
Publicado: (2022)

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients
por: Yu, Rentao, et al.
Publicado: (2016)

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients
por: Xu, Fei, et al.
Publicado: (2021)

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
por: Kim, Do Young, et al.
Publicado: (2023)

Corrigendum: Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients
por: Yu, Rentao, et al.
Publicado: (2016)

PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
por: Tartaglione, Sara, et al.
Publicado: (2021)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
por: Kaneko, Shun, et al.
Publicado: (2022)

PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients
por: Suttichaimongkol, Tanita, et al.
Publicado: (2023)

PIVKA-II as a surrogate marker for prognosis in patients with localized hepatocellular carcinoma receiving stereotactic body radiotherapy
por: Cho, Ick Joon, et al.
Publicado: (2022)

Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population
por: Zheng, Kepu, et al.
Publicado: (2023)

Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation
por: Si, Yuan-Quan, et al.
Publicado: (2020)

Abnormal Prothrombin (PIVKA-II) Expression in Canine Tissues as an Indicator of Anticoagulant Poisoning
por: Maniscalco, Lorella, et al.
Publicado: (2021)

Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers
por: An, Shu, et al.
Publicado: (2023)

Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma
por: Villalba-López, Francisco, et al.
Publicado: (2023)

Effect of PIVKA‐II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery
por: Cai, Yunshi, et al.
Publicado: (2023)

Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data
por: Yu, Rentao, et al.
Publicado: (2017)

Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma
por: Wang, Xiumei, et al.
Publicado: (2017)

The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels in Patients without Hepatocellular Carcinoma
por: Kang, Keunhee, et al.
Publicado: (2015)

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma
por: Tran, Vinh Thanh, et al.
Publicado: (2023)

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis
por: Liu, Siyu, et al.
Publicado: (2022)

Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population
por: Yu, Rentao, et al.
Publicado: (2015)

Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma
por: Ma, Xiao-Lu, et al.
Publicado: (2018)

PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients
por: Saitta, Carlo, et al.
Publicado: (2017)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
por: Sun, Xuqi, et al.
Publicado: (2021)

Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients
por: Hadi, Hana, et al.
Publicado: (2022)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Assessment of Serum Macrophage Migration Inhibitory Factor (MIF) as an Early Diagnostic Marker of Leptospirosis
por: Sumaiya, Krishnamoorthi, et al.
Publicado: (2022)

Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma
por: Park, Hana, et al.
Publicado: (2013)

PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma
por: Li, Tao, et al.
Publicado: (2019)

The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China
por: Ji, Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tt3e0sn134i6vgk3nhdnedb3rf